



For Immediate Release: January 13, 2025

Contact: Ellen Berlin, Dana-Farber Cancer Institute, ellen_berlin@dfci.harvard.edu
Claire Parisel, Gustave Roussy, claire.parisel@gustaveroussy.fr

Dana-Farber and Gustave Roussy announce 2025 Transatlantic Exchange scientific program to focus on Radioligand Therapy

Dana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Fourth Transatlantic Exchange in Oncology Conference topic will be “Radiopharmaceutical Therapy Meets Oncology.” The meeting, supported by L'Institut Servier, will be held in-person on March 19, 2025, at [Hyatt Regency Etoile Hotel](#) and livestreamed.

Leaders from both organizations, recognized globally for their expertise, will present on such topics as: Precision Oncology and molecular imaging – early detection; How to go from non-Radio-labelled target to a Radio-labelled active product; Latest clinical applications; and Perspectives from Academia and Industry on Radioligand Therapies.

The meeting will be chaired by Professor Toni Choueiri, medical director of International Strategic Initiatives and director of the Lank Center for Genitourinary Oncology at Dana-Farber and Harvard Medical School and Professor Karim Fizazi, Gustave Roussy and Université Paris-Saclay, head of the International Academic Network at Gustave Roussy.

The Keynote speaker is Michael Morris, MD, FASCO, Prostate Cancer Section Head, Genitourinary Oncology, Steven A. Greenberg Chair in Prostate Cancer Research at Memorial Sloan Kettering Cancer Center (NYC, USA). His keynote presentation will discuss Seeing beyond VISION: Designing Radioligand Therapy trials that yield a survival benefit.

"Through this scientific conference, our global colleagues share recent discoveries, ranging from basic to translational research as well as best practices in clinical care. The panels of expert faculty from both centers will discuss recent advances and future directions of radiopharmaceutical therapy in oncology. This meeting and the previous programs enhance our collaborative approach and facilitate exchange of information and talents toward one goal: curing cancer," said Choueiri.

"As we look to the future of patient care, radioligand therapies is crucial in future strategies. Gustave Roussy is one of the current leaders in radio-labelled-therapies with long tradition,

promoting and developing from first in human to phase III trials in all types of cancer and a dedicated patient care journey. Advancing from non-radio-labelled targets to active radio-labelled products opens transformative possibilities for precision medicine. Gustave Roussy and Dana-Farber are at the forefront of these disciplines, driving cutting-edge research and clinical applications that hold promise for truly improving outcomes and offering hope to patients worldwide," said Professor Fabrice Barlesi, MD, PhD, Université Paris-Saclay and general director of Gustave Roussy.

This Transatlantic Exchange Conference is part of a collaboration agreement between Dana-Farber and Gustave Roussy with the support of L'Institut Servier, a non-profit organization supporting improvements in healthcare via the promotion of academic research and scientific exchange. The collaboration includes annual conferences alternating between Boston, MA, USA and Paris, France, and a biennial fellowship program for several young researchers, post-doctoral students from Gustave Roussy, who are hosted in research laboratories of Dana-Farber.

Previous meetings have focused on Immuno-Oncology, AI/Data Science in Oncology and Liquid Biopsy. The first meeting took place in Boston, MA, USA, in May 2022.

"L'Institut Servier is proud to support this program, which offers a unique opportunity to explore a global research topic in oncology through the perspectives of two specialized oncology centers in Europe and the U.S. These scientific exchanges have the potential to aid many other oncology centers worldwide in addressing practical questions and interfacing with leading experts in the field," said Patrick Therasse, MD, PhD, managing director of L'Institut Servier.

The meeting is presented with the support of Medscape Medical Affairs.

This meeting is free and open to healthcare professionals with an interest in oncology. Virtual registration is now open: please register at <https://events.medscapelive.org/website/82041/>

Anyone wishing to attend the meeting in person may do so by selecting the in-person registration option here: <https://events.medscapelive.org/website/82041/>